Literature DB >> 16703406

Antiproliferative effects of somatostatin analogs in pituitary adenomas.

Maria Chiara Zatelli1, Daniela Piccin, Maria Rosaria Ambrosio, Marta Bondanelli, Ettore C degli Uberti.   

Abstract

The antisecretory effects of somatostatin (SRIF) and its analogs are widely recognised and provide the basis for treatment of hormonal hypersecretion in pituitary adenomas, especially in the settings of acromegaly. Evidence for an antiproliferative effect of these compounds has also been provided. This review focuses on the mechanisms transducing the antiproliferative effects of SRIF and its analogs on pituitary adenomas, and on the clinical consequences on tumor volume of pharmacological treatment of pituitary adenomas with these drugs.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16703406     DOI： 10.1007/s11102-006-7822-6

Source DB:  PubMed          Journal:  Pituitary        ISSN： 1386-341X            Impact factor:   3.599


  79 in total

1.  Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin.

Authors:  P Dasgupta; A T Singh; R Mukherjee
Journal:  Biochem Biophys Res Commun       Date:  1999-06-07       Impact factor: 3.575

Review 2.  Opportunities in somatostatin research: biological, chemical and therapeutic aspects.

Authors:  Gisbert Weckbecker; Ian Lewis; Rainer Albert; Herbert A Schmid; Daniel Hoyer; Christian Bruns
Journal:  Nat Rev Drug Discov       Date:  2003-12       Impact factor: 84.694

3.  Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers.

Authors:  M Rocheville; D C Lange; U Kumar; R Sasi; R C Patel; Y C Patel
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

Review 4.  Peptides in the brain: the new endocrinology of the neuron.

Authors:  R Guillemin
Journal:  Science       Date:  1978-10-27       Impact factor: 47.728

5.  Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice.

Authors:  C Cristina; G Díaz-Torga; A Baldi; A Góngora; M Rubinstein; M J Low; D Becú-Villalobos
Journal:  Endocrinology       Date:  2005-04-07       Impact factor: 4.736

6.  In vivo and in vitro plasma disappearance and metabolism of somatostatin-28 and somatostatin-14 in the rat.

Authors:  Y C Patel; T Wheatley
Journal:  Endocrinology       Date:  1983-01       Impact factor: 4.736

7.  Octreotide treatment does not affect the size of most non-functioning pituitary adenomas.

Authors:  M Gasperi; L Petrini; R Pilosu; M Nardi; A Marcello; F Mastio; L Bartalena; E Martino
Journal:  J Endocrinol Invest       Date:  1993 Jul-Aug       Impact factor: 4.256

8.  A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.

Authors:  Joost van der Hoek; Wouter W de Herder; Richard A Feelders; Aart-Jan van der Lely; Piet Uitterlinden; Viktor Boerlin; Christian Bruns; Kwai W Poon; Ian Lewis; Gisbert Weckbecker; Tillmann Krahnke; Leo J Hofland; Steven W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

9.  Morphological effects of octreotide on growth hormone-producing pituitary adenomas.

Authors:  S Ezzat; E Horvath; A G Harris; K Kovacs
Journal:  J Clin Endocrinol Metab       Date:  1994-07       Impact factor: 5.958

10.  Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.

Authors:  Y Greenman; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958
View more
  5 in total

1.  Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Authors:  Mark Gruppetta; Robert Formosa; Sharon Falzon; Sabrina Ariff Scicluna; Edward Falzon; James Degeatano; Josanne Vassallo
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

2.  Antiproliferative effects of somatostatin analogs in endocrine tumours.

Authors:  Maria Chiara Zatelli
Journal:  F1000 Med Rep       Date:  2009-05-08

Review 3.  Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.

Authors:  Richard A Feelders; Leo J Hofland; Maarten O van Aken; Sebastian J Neggers; Steven W J Lamberts; Wouter W de Herder; Aart-Jan van der Lely
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

4.  Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization.

Authors:  Michael Grant; Haydar Alturaihi; Philippe Jaquet; Brian Collier; Ujendra Kumar
Journal:  Mol Endocrinol       Date:  2008-07-24

5.  Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines.

Authors:  A Dicitore; D Saronni; G Gaudenzi; S Carra; M C Cantone; M O Borghi; L Persani; G Vitale
Journal:  J Endocrinol Invest       Date:  2021-06-14       Impact factor: 4.256
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.